Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease
about
New mutations in ZFPM2/FOG2 gene in tetralogy of Fallot and double outlet right ventricleNKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferationEpigenetic mechanisms in cardiac development and diseaseGenetics of congenital heart disease: the glass half emptyCrystal Structure of the Human NKX2.5 Homeodomain in Complex with DNA TargetComplex SUMO-1 regulation of cardiac transcription factor Nkx2-5Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoproteinNKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity.Transient early embryonic expression of Nkx2-5 mutations linked to congenital heart defects in human causes heart defects in Xenopus laevis.Point mutations in murine Nkx2-5 phenocopy human congenital heart disease and induce pathogenic Wnt signaling.Expression of sumoylation deficient Nkx2.5 mutant in Nkx2.5 haploinsufficient mice leads to congenital heart defects.Examining the cardiac NK-2 genes in early heart development.Cardiac transcription factor Nkx2.5 is downregulated under excessive O-GlcNAcylation condition.The ambiguous role of NKX2-5 mutations in thyroid dysgenesis.Functional zebrafish studies based on human genotyping point to netrin-1 as a link between aberrant cardiovascular development and thyroid dysgenesisMutations that affect the ability of the vnd/NK-2 homeoprotein to regulate gene expression: transgenic alterations and tertiary structureNKX2-5 mutations in an inbred consanguineous population: genetic and phenotypic diversity.Cardiac chamber formation: development, genes, and evolution.Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction.An Orthologous Epigenetic Gene Expression Signature Derived from Differentiating Embryonic Stem Cells Identifies Regulators of CardiogenesisNKX2-5 mutations causative for congenital heart disease retain functionality and are directed to hundreds of targets.Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoproteinIrx3 is required for postnatal maturation of the mouse ventricular conduction systemEvolutionary conservation of Nkx2.5 autoregulation in the second heart field.Functional characterization of a novel mutation in NKX2-5 associated with congenital heart disease and adult-onset cardiomyopathy.NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling.Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer.Stem cell models of cardiac development and disease.Mutational spectrum of the NKX2-5 gene in patients with lone atrial fibrillationFrom molecular mechanisms of cardiac development to genetic substrate of congenital heart diseases.Pendrin is a novel in vivo downstream target gene of the TTF-1/Nkx-2.1 homeodomain transcription factor in differentiated thyroid cells.Jarid2 is among a set of genes differentially regulated by Nkx2.5 during outflow tract morphogenesis.Novel NKX2-5 mutations in diseased heart tissues of patients with cardiac malformations.Desmin enters the nucleus of cardiac stem cells and modulates Nkx2.5 expression by participating in transcription factor complexes that interact with the nkx2.5 gene.A mouse model of human congenital heart disease: high incidence of diverse cardiac anomalies and ventricular noncompaction produced by heterozygous Nkx2-5 homeodomain missense mutation.GATA5 loss-of-function mutation responsible for the congenital ventriculoseptal defect.Biochemical Analyses of Csx/Nkx2.5 Mutants and Their Structure–Function Relationship.Genetic abnormalities in FOXP1 are associated with congenital heart defects.The c.63A>G polymorphism in the NKX2.5 gene is associated with thyroid hypoplasia in children with thyroid dysgenesis.Functional dissection of sequence-specific NKX2-5 DNA binding domain mutations associated with human heart septation defects using a yeast-based system.
P2860
Q24298150-EC95901F-A099-41EE-BCAA-0019B924B906Q24317081-08586DD4-12D2-4E10-A5B4-9805B011014CQ26853290-DB16E388-690C-4C5A-9170-338656F22CE1Q26862793-1AEEFBE5-C70A-464E-80D6-459C808DA651Q27671009-711E2BD0-004D-4E33-9BBE-0E45F96A67ABQ28477049-20FF5627-B0C6-4C66-9EE7-250D8EDC44DCQ28578096-B9354F26-338F-4CED-9773-7F3181F4203BQ30361778-0D131039-8E31-474E-8092-BCB1DF754C8AQ30480671-B22C80C0-55D3-49DA-9A25-978E360CEEDFQ30842375-6CF84FED-1BFD-4187-B537-74B486771E41Q33934076-BE6E2342-97F9-4FCC-AEE9-D6227CBE4939Q34308498-D9AEDE59-B6E6-40E0-8BFF-A3D5123C1028Q34311803-F33C630D-D3C7-4CCD-AA42-FEDECD79A74CQ34534411-EC245241-57DF-4377-A2DF-40B187846FC6Q34745253-5740E30A-A6BE-4838-A7EF-1E998B4C104CQ34866727-D2533F3A-70DA-4546-BB5E-9A7C54EA979EQ35153273-B4A5A9DA-F109-48D2-9097-97769F69C69BQ35541868-1FAB4B83-28C5-46D7-8F2B-F88929953814Q35803643-3FADFD8A-92E7-4763-98C6-BE53E498DF98Q35814820-4D06C97D-007F-4EB3-A863-6968FD479B6FQ35992694-2092498A-74D4-482B-87AC-DA2EF0740541Q36072681-5F56D68F-FD13-4D5A-9F82-7A5C6C7F8698Q36501199-2F44E343-E851-4416-BAA3-011CCCCA3DC5Q36545329-13DDE08D-7AC1-429C-851E-53DE79B26962Q37275558-F4851CF9-E208-48D6-8EF6-5A9B2FCAF786Q37294787-06562236-245A-4543-9C64-3C3212B0E73BQ37424378-7658D882-9FB9-4544-A360-3FBF055CC57FQ37640325-F8F0AD4A-CADC-410C-B7D6-38AF13C46063Q37730257-1DCA1257-BD10-49AC-AFFA-A80804CCB741Q37749840-D403AA4C-3AB3-468A-8CEF-69A5CD143C51Q38319293-9266C621-3CEA-4928-B475-6279BBD44136Q38343279-49748DAA-0CEE-49B0-8527-A902511E9CB8Q38737280-AB1EC3FB-A8B6-4C94-A04E-34AA61A47BB6Q39948025-D102DEC8-8EB2-486A-A53B-845244FD2936Q42186727-9F962933-2C85-4B20-869E-6D0FB8F99F08Q43741626-DEAD1143-02EE-409E-9CF8-12FA0CBD7FF8Q46422633-7ADEE4C2-C1ED-4FB7-B729-181C6D45878EQ47144137-33C41637-3A33-4DC5-9D5B-09541B86D46BQ53326779-8CDFD3EF-20A6-4D3D-9B5C-03C8ABB4285CQ53621281-0B7FEB4C-CFE3-410A-B375-817BEB8F2F79
P2860
Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Loss of function and inhibitor ...... with congenital heart disease
@ast
Loss of function and inhibitor ...... with congenital heart disease
@en
Loss of function and inhibitor ...... with congenital heart disease
@nl
type
label
Loss of function and inhibitor ...... with congenital heart disease
@ast
Loss of function and inhibitor ...... with congenital heart disease
@en
Loss of function and inhibitor ...... with congenital heart disease
@nl
prefLabel
Loss of function and inhibitor ...... with congenital heart disease
@ast
Loss of function and inhibitor ...... with congenital heart disease
@en
Loss of function and inhibitor ...... with congenital heart disease
@nl
P2093
P2860
P356
P1476
Loss of function and inhibitor ...... with congenital heart disease
@en
P2093
C E Seidman
D W Benson
H Kasahara
J G Seidman
J J Schott
P2860
P304
P356
10.1172/JCI9860
P407
P577
2000-07-01T00:00:00Z